Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Key insights to understand the immunogenicity of FVIII products.

Thrombosis and haemostasis - 31 Aug 2016

Goudemand Jenny, Peyvandi Flora, Lacroix-Desmazes Sébastien

Abstract excerpt

The treatment of haemophilia has made significant progress in recent decades, and patients are now being treated safely with great clotting products. However, inhibitor development remains the largest problem, particularly in children. Consequently, the haemostasis that was obtained with traditional clotting factors is not being achieved. Moreover, inhibitor complications translate into adult life and there are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Coagulation Factors
Share to Endocytosis
Share to Factor VIII

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hemophilia A

Share to Hemostasis

Share to Protein Conformation

Share to Thrombosis

Share to von Willebrand Factor

Source

Identifiers

PMID: 27528279
DOI: 10.1160/TH16-01-0048

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Key insights to understand the immunogenicity of FVIII products.PMID 27528279Read ↗

Prevention of inhibitor development in hemophilia A in 2016. A glimpse into the future?Semantic proximity Read ↗

Biological considerations of plasma-derived and recombinant factor VIII immunogenicitySemantic proximity Read ↗

Development of inhibitors in hemophilia A: An illustrated reviewSemantic proximity Read ↗

Blood coagulation factor VIII: An overview.Semantic proximity Read ↗

The Evolution of Hemophilia Care: Clinical and Laboratory Advances, Opportunities, and ChallengesSemantic proximity Read ↗

Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?Semantic proximity Read ↗

A close insight to factor VIII inhibitor in the congenital hemophilia A.Semantic proximity Read ↗

Haemophilia.Semantic proximity Read ↗

Assessing risk factors: prevention of inhibitors in haemophilia.Semantic proximity Read ↗

Factor VII deficiency: defining the clinical picture and optimizing therapeutic options.Semantic proximity Read ↗

FVIII Immunogenicity-Bioinformatic Approaches to Evaluate Inhibitor Risk in Non-severe Hemophilia A.Semantic proximity Read ↗

The incidence and treatment of bleeding episodes in non-severe haemophilia A patients with inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.